Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Innovations GroupLSE:SUN Debt-to-Equity is 0.09 as of Dec. 2025, which is 47% below its 10-year median of 0.17. The stock has 2 warning signs investors should review. Among 699 Medical Devices & Instruments companies, Surgical Innovations Group ranks better than 71.96% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Surgical Innovations Group's Debt-to-Equity or its related term are showing as below:
LSE:SUN'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.17 Max: 0.3
Current: 0.09
During the past 13 years, the highest Debt-to-Equity Ratio of Surgical Innovations Group was 0.30. The lowest was 0.01. And the median was 0.17.
LSE:SUN's Debt-to-Equity is ranked better than 71.96% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs LSE:SUN: 0.09
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Surgical Innovations Group Debt-to-Equity Related Terms
Surgical Innovations Group Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:SUN vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Surgical Innovations Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Innovations Group Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Surgical Innovations Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Surgical Innovations Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Innovations Group (LSE:SUN) has a Debt-to-Equity of 0.09 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Surgical Innovations Group and its competitors. This is 47% below median its historical median of 0.17. Over the past decade, Surgical Innovations Group's Debt-to-Equity has ranged from 0.01 to 0.30. According to the industry distribution chart, Surgical Innovations Group ranks #196 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 28%.
Is Surgical Innovations Group's Debt-to-Equity too high?
Surgical Innovations Group's current Debt-to-Equity of 0.09 is 47% below median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.30. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Surgical Innovations Group's value of 0.09 is 62.5% below this industry median. Based on the distribution chart, Surgical Innovations Group ranks #196 out of 699 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Surgical Innovations Group's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Surgical Innovations Group ranks #196 out of 699 companies for Debt-to-Equity. This puts Surgical Innovations Group in the upper half of its industry. The industry median Debt-to-Equity is 0.24. Surgical Innovations Group's value of 0.09 is 62.5% below this benchmark. Historically, Surgical Innovations Group's own Debt-to-Equity has ranged from 0.01 to 0.30 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 0.24, Surgical Innovations Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Innovations Group's current Debt-to-Equity of 0.09 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Surgical Innovations Group and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Innovations Group's current Debt-to-Equity is 0.09, which is 47% below median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Innovations Group stock overvalued right now?
Surgical Innovations Group (LSE:SUN) has a current Debt-to-Equity of 0.09. The current Debt-to-Equity is 0.09, which is 47% below median its 10-year median of 0.17 and 62.5% below the Medical Devices & Instruments industry median of 0.24. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Surgical Innovations Group (LSE:SUN), the current Debt-to-Equity is 0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Surgical Innovations Group PLC is involved in the design, development, manufacture, and sale of devices for use in minimally invasive surgery (SI Brand), along with its label products through original equipment manufacturer (OEM) relationships, including precision engineering markets (PE). The Company's operating segments are SI Brand, OEM, and Distribution. The majority of its revenue is generated from the SI Brand segment, which is involved in the research, development, manufacture, and distribution of SI-branded minimally invasive devices. Geographically, the group derives a majority of its revenue from the United Kingdom, followed by Europe, the United States, the Asia-Pacific region, and the Rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SUN has been successfully added to your 
